Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.

Saved in:
Bibliographic Details
Title: Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.
Authors: Parker N; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway. nadine.parker@medisin.uio.no., Koch E; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway.; Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway., Shadrin AA; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway., Fuhrer J; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway., Hindley GFL; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway.; Department of Psychiatry, Lovisenberg Diaconal Hospital, Oslo, Norway., Stinson SE; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway., Jaholkowski P; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway., Tesfaye M; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway.; Department of Clinical Science, University of Bergen, Bergen, Norway., Dale AM; Multimodal Imaging Laboratory, University of California, San Diego, La Jolla, CA, USA.; Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.; Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA.; Department of Radiology, University of California, San Diego, La Jolla, CA, USA., Wingo TS; Department of Neurology, University of California, Davis, Sacramento, CA, USA., Wingo AP; Department of Psychiatry, University of California, Davis, Sacramento, CA, USA.; Division of Mental Health, VA Medical Center, Mather, CA, USA., Frei O; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway.; Department of Pharmacy, Section for Pharmacology and Pharmaceutical Biosciences, University of Oslo, Oslo, Norway., O'Connell KS; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway., Smeland OB; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway., Andreassen OA; Centre for Precision Psychiatry, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Oslo, Norway. ole.andreassen@medisin.uio.no.
Source: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2026 Jun; Vol. 51 (7), pp. 1300-1309. Date of Electronic Publication: 2026 Mar 07.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8904907 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1740-634X (Electronic) Linking ISSN: 0893133X NLM ISO Abbreviation: Neuropsychopharmacology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1740-634X
DOI:10.1038/s41386-026-02380-8